The US investment firm Bioluminescence Ventures (BLV) has emerged from stealth with $477 million to finance biotech companies developing first-in-class or best-in-class disease treatments.
The London and New York-based gene therapy player MeiraGTx Holdings has received a $30 million investment from Sanofi in addition to potential strategic deals with the big pharma company down the road.
She has a proven track record of leading and mentoring start-ups in the biotechnology field, with her proven abilities in investment and portfolio management, investments, risk management, and business strategy development, Maria is a go-to expert in...
HexisLab, a UK biotech company, has secured a £490,000 funding grant from Innovate UK to develop a scale-up manufacturing process for its novel sustainable and green ingredients.
Biopharma industry in the US is rooted in a strong R&D sector, with the employment percentage being three times larger than the industry average, suggests PhRMA.
EQT VIII Fund set to acquire majority interest in plasmid DNA supplier Aldevron, announces investments to support the expansion of its production capacity.
Johnson & Johnson has unveiled a vaccine facility in Leiden, the Netherlands, which will focus on R&D, technological development, and large-scale production of vaccines for late-stage clinical trials.
Following a ¥14bn ($125m) investment in April, Fujifilm Corporation has committed a further ¥3.2bn across its biologics contract manufacturing business.
Bioprocessing suppliers have recently expressed optimism in the sector despite a slowdown in growth, and one expert believes this will drive investment in new tech and markets.
Lonza expects to complete its $5.5bn (€5.2bn) takeover of Capsugel SA in the next few days having secured approval from competition authorities around the world.
Merck KGaA’s corporate venture division has created an immune-oncology company based on a mixture of small and large molecule drugs, including Merck and Pfizer’s Bavencio (avelumab).
There is a growing trend among vendors to integrate automation technologies into their offerings says a bioprocessing expert, as GE Healthcare invests in its partner Zenith.
CMOs will struggle to compete with large in-house capacity investments, according to Results Healthcare which predicts a decline in outsourced biomanufacturing.
A lack of investment and government support has stunted biomanufacturing in India, but Biocon says this will change through the country’s 'Make in India' programme.
GE Healthcare says a $7m investment will triple clean-room capacity and add automated production lines at its single-use tech manufacturing facility in Massachusetts.
AstraZeneca says it will use the acquired plant as a warehouse to support biomanufacturing operations at a nearby facility, previously purchased from Amgen.
Novartis will continue investing in its manufacturing network to support a biologics pipeline which includes five new biosimilars it expects to launch by 2020.
Pfizer broke ground on its new Andover, MA-based biologics clinical manufacturing facility this week, which will feature single-use and disposable technologies.
EAG has further invested in ABC Laboratories' capacity and analytical capabilities in order to help meet demand for high-end biopharmaceutical analysis.
Sartorius will invest around 10% of its annual revenues into its manufacturing network to support continued double-digit growth of its bioprocessing equipment business.
Pfizer has invested $46m in separate collaborations with four R&D companies specialising in developing ADCs, immuno-oncology candidates and gene-therapies.
Merck & Co. will invest €11.5m ($12.5m) at a plant in Ireland to manufacture its oncology drug Keytruda, an anti-PD1 mAb recently approved by the US FDA.